Cargando…

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?

CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative breast cancer. Three CDK 4/6 inhibitor drugs are currently approved and available, including Palbociclib, Ribociclib and Abemaciclib. All th...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhade, Amol, Van Wambeke, Simon, Gyawali, Bishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470169/
https://www.ncbi.nlm.nih.gov/pubmed/36200010
http://dx.doi.org/10.3332/ecancer.2022.ed124
_version_ 1784788789864955904
author Akhade, Amol
Van Wambeke, Simon
Gyawali, Bishal
author_facet Akhade, Amol
Van Wambeke, Simon
Gyawali, Bishal
author_sort Akhade, Amol
collection PubMed
description CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative breast cancer. Three CDK 4/6 inhibitor drugs are currently approved and available, including Palbociclib, Ribociclib and Abemaciclib. All three of these drugs have similar mechanism of action and other pharmacokinetic and pharmaco-dynamic properties and hold equivalent positions in cancer care guidelines. Surprisingly, however, in the adjuvant setting of early breast cancer, two trials of palbociclib have failed to show any benefit while abemaciclib has shown some early benefits in disease-free survival and has received approval for its use in adjuvant setting. In this article, we explore several reasons for this discrepancy in the results of CDK4/6 inhibitors in the adjuvant setting. We also question if we should already adopt adjuvant abemaciclib in our clinical practice given the uncertainty in data.
format Online
Article
Text
id pubmed-9470169
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-94701692022-10-04 CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner? Akhade, Amol Van Wambeke, Simon Gyawali, Bishal Ecancermedicalscience Editorial CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative breast cancer. Three CDK 4/6 inhibitor drugs are currently approved and available, including Palbociclib, Ribociclib and Abemaciclib. All three of these drugs have similar mechanism of action and other pharmacokinetic and pharmaco-dynamic properties and hold equivalent positions in cancer care guidelines. Surprisingly, however, in the adjuvant setting of early breast cancer, two trials of palbociclib have failed to show any benefit while abemaciclib has shown some early benefits in disease-free survival and has received approval for its use in adjuvant setting. In this article, we explore several reasons for this discrepancy in the results of CDK4/6 inhibitors in the adjuvant setting. We also question if we should already adopt adjuvant abemaciclib in our clinical practice given the uncertainty in data. Cancer Intelligence 2022-08-30 /pmc/articles/PMC9470169/ /pubmed/36200010 http://dx.doi.org/10.3332/ecancer.2022.ed124 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Akhade, Amol
Van Wambeke, Simon
Gyawali, Bishal
CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
title CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
title_full CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
title_fullStr CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
title_full_unstemmed CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
title_short CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
title_sort cdk 4/6 inhibitors for adjuvant therapy in early breast cancer—do we have a clear winner?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470169/
https://www.ncbi.nlm.nih.gov/pubmed/36200010
http://dx.doi.org/10.3332/ecancer.2022.ed124
work_keys_str_mv AT akhadeamol cdk46inhibitorsforadjuvanttherapyinearlybreastcancerdowehaveaclearwinner
AT vanwambekesimon cdk46inhibitorsforadjuvanttherapyinearlybreastcancerdowehaveaclearwinner
AT gyawalibishal cdk46inhibitorsforadjuvanttherapyinearlybreastcancerdowehaveaclearwinner